8.2 Cost-effectiveness and health economic implications The elevated cost of acquisition of GLP-1 receptor agonists convey major challenges for healthcare systems, with yearly treatment expenses between $10,000 and $15,000 USD, markedly surpassing those of conventional diabetic drugs (Kong et al
This also boosts protein production in muscles and aids in their repair (1)
Wegovy specifically licensed for weight management) [1] [6] Liraglutide (Victoza for diabetes
The clinical data on semaglutide shows that the most meaningful results, including measurable body composition changes and improved metabolic markers, develop between months two and six of consistent use
These improvements may include: Lower blood pressure Reduced blood sugar and cholesterol levels Healthier weight Semaglutide injection helps individuals achieve and maintain weight loss by controlling blood sugar levels and regulating appetite, which can contribute to better heart health
Targeted, multi-modal interventions can help significantly, and the research proves it